Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.

DPH | IL

Overview

Corporate Details

ISIN(s):
US2434351043
LEI:
213800J4UVB5OWG8VX82
Country:
United Kingdom
Address:
24 CHESHIRE AVENUE, CW9 7UA NORTHWICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dechra Pharmaceuticals PLC is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacture, marketing, and sales of high-quality products designed to improve animal health and welfare. Its portfolio includes a range of drugs and therapies for the prevention, diagnosis, and treatment of conditions in animals, with a focus on companion animals like dogs, cats, and horses. Dechra markets its products exclusively to veterinarians worldwide, positioning itself as a dedicated partner to the profession. The company also provides educational support through resources like the Dechra Academy to help veterinary professionals stay current with industry advancements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-23 17:41
Major Shareholding Notification
Holding(s) in Company
English 23.4 KB
2024-01-18 16:14
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2024-01-18 11:11
Major Shareholding Notification
Holding(s) in Company
English 26.8 KB
2024-01-17 15:01
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-17 13:01
Delisting Announcement
Holding(s) in Company
English 51.4 KB
2024-01-17 13:00
Major Shareholding Notification
Holding(s) in Company
English 54.9 KB
2024-01-17 12:16
Major Shareholding Notification
Holding(s) in Company
English 29.1 KB
2024-01-17 09:15
Delisting Announcement
Cancellation of listing and admission to trading
English 24.9 KB
2024-01-17 08:30
Major Shareholding Notification
Holding(s) in Company
English 21.6 KB
2024-01-16 17:54
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2024-01-16 16:25
Major Shareholding Notification
Form 8.3 - Dechra Pharmaceuticals plc
English 46.1 KB
2024-01-16 15:43
Major Shareholding Notification
Holding(s) in Company
English 31.2 KB
2024-01-16 13:04
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-16 11:15
Post-Annual General Meeting Information
Scheme of Arrangement becomes Effective
English 45.8 KB
2024-01-16 10:00
Major Shareholding Notification
Holding(s) in Company
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Dechra Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dechra Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.